Wed, November 18, 2009
[ Wed, Nov 18th 2009 ]: Market Wire
Oncolytics Biotech(R) Inc. Announces Terms of Unit Offering
[ Wed, Nov 18th 2009 ]: Market Wire
DIAGNOS: Local Model on Metanor Resources Barry Gold Project
[ Wed, Nov 18th 2009 ]: Market Wire
Harte-Hanks and MedImmune Win Medical Marketing & Media Gold Award
[ Wed, Nov 18th 2009 ]: Market Wire
San West, Inc. Announces Consulting Agreement Wit .. Implement a Strategic Investor Relations Campaign
[ Wed, Nov 18th 2009 ]: Market Wire
InternetArray Announces BidSellBuy Open House
[ Wed, Nov 18th 2009 ]: Market Wire
CTD Holdings, Inc. Announces Profitable 3rd Quarter Results
[ Wed, Nov 18th 2009 ]: Market Wire
AVI BioPharma, Inc. to Present at Transformationa .. dical Technologies Initiative (TMTI) Industry Day
Tue, November 17, 2009
[ Tue, Nov 17th 2009 ]: Market Wire
Oncolytics Biotech(R) Inc. Collaborators Present .. ults in Advanced Solid Cancers with a Focus on th
[ Tue, Nov 17th 2009 ]: Market Wire
Microbix Signs Marketing Agreement For Kinlytic(R)(Urokinase) In Growing Middle East Region
[ Tue, Nov 17th 2009 ]: Market Wire
ViStra Growth Partners to Begin Accepting Clients
[ Tue, Nov 17th 2009 ]: Market Wire
Cytokinetics Presents Non-Clinical Data From Its .. rogram at the 2009 Scientific Sessions of the Ame
[ Tue, Nov 17th 2009 ]: Market Wire
Adeona Pharmaceuticals Announces Third Quarter 2009 Results and Achievements
[ Tue, Nov 17th 2009 ]: Market Wire
CONMED Linvatec Announces Launch of Novel Biocomp .. lated Matryx(TM) Biocomposite Interference Screws
[ Tue, Nov 17th 2009 ]: Market Wire
Agennix AG Schedules Conference Call on November .. d to Discuss Third Quarter 2009 Financial Results
Mon, November 16, 2009
[ Mon, Nov 16th 2009 ]: Market Wire
iShares Announces Launch of iShares(R) Diversified Alternatives Trust (ALT)
[ Mon, Nov 16th 2009 ]: Market Wire
Vicor Technologies Announces Filing of 10-Q on November 13, 2009
[ Mon, Nov 16th 2009 ]: Market Wire
Sunesis Reports Financial Results for the Third Quarter of 2009
[ Mon, Nov 16th 2009 ]: Market Wire
Oncolytics Biotech(R) Inc. Collaborators to Prese .. Results in Advanced Solid Cancers with a Focus on
[ Mon, Nov 16th 2009 ]: Market Wire
Protox reports 2009 third quarter results
[ Mon, Nov 16th 2009 ]: Market Wire
China INSOnline Reports 27% Gain in First Quarter Net Income on 6% Decline in Revenues
[ Mon, Nov 16th 2009 ]: Market Wire
CONMED Linvatec Announces Launch of Bullseye(TM) Anatomic Cruciate Reconstruction System
Sun, November 15, 2009
[ Sun, Nov 15th 2009 ]: Market Wire
The Medicines Company's Full Analysis of CHAMPION .. or Significantly Improves Patient Outcomes Follow
Fri, November 13, 2009
[ Fri, Nov 13th 2009 ]: Market Wire
BioSyntech announces second quarter fiscal 2010 financial results
[ Fri, Nov 13th 2009 ]: Market Wire
MedaSorb Technologies Corporation Provides Clinical Update
[ Fri, Nov 13th 2009 ]: Market Wire
MedaSorb Technologies Corporation Announces Q3 2009 Results and Files Form 10-Q, Quarterly Report
[ Fri, Nov 13th 2009 ]: Market Wire
Quest PharmaTech Announces the Passing of One of its Directors
[ Fri, Nov 13th 2009 ]: Market Wire
SemBioSys announces third quarter 2009 financial and operational results
[ Fri, Nov 13th 2009 ]: Market Wire
San West Inc. Reports Third-Quarter 2009 Results
[ Fri, Nov 13th 2009 ]: Market Wire
Agennix AG to Present at Lazard Capital Markets 6th Annual Healthcare Conference
Thu, November 12, 2009
[ Thu, Nov 12th 2009 ]: Market Wire
International Drug & Explosives Detection Firm ID .. Retail Marketing Progress Through Earthbound, LLC
[ Thu, Nov 12th 2009 ]: Market Wire
Horizon Health International Receives eBay Vendor Status as Part of its Product Awareness Campaign
[ Thu, Nov 12th 2009 ]: Market Wire
Merc Discovers New Gold Zone Within the Red Mount .. s Mineralization at Damoti Lake Gold Project, NWT
[ Thu, Nov 12th 2009 ]: Market Wire
(NYSE Amex: DXR) Daxor Corporation Announces Third Quarter 2009 Earnings
[ Thu, Nov 12th 2009 ]: Market Wire
Spectral announces third quarter 2009 results
[ Thu, Nov 12th 2009 ]: Market Wire
Medical Facilities Corporation Reports 2009 Third Quarter Financial Results
[ Thu, Nov 12th 2009 ]: Market Wire
Reflect Scientific Enters Cooperative Marketing A .. iner for Patented Refrigerated Truck Cooling Syst
Wed, November 11, 2009
[ Wed, Nov 11th 2009 ]: Market Wire
HearUSA and Veterans Care Plus Offer More Affordable Hearing Care to America's Veterans
[ Wed, Nov 11th 2009 ]: Market Wire
Given Imaging to Present at the 6th Annual Lazard Capital Markets Healthcare Conference
[ Wed, Nov 11th 2009 ]: Market Wire
Amarillo Biosciences Comments on New Findings of .. Animals and Potential Effect on Human Infections
[ Wed, Nov 11th 2009 ]: Market Wire
Auxilium Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
[ Wed, Nov 11th 2009 ]: Market Wire
Premium Brands Holdings Corporation Announces Intention to Make Normal Course Issuer Bid
[ Wed, Nov 11th 2009 ]: Market Wire
&;AElig;terna Zentaris Reports Third Quarter 2009 Financial and Operating Results
[ Wed, Nov 11th 2009 ]: Market Wire
TSO3 announces financial results for Q3 2009 and updates on negotiations with 3M
Tue, November 10, 2009
[ Tue, Nov 10th 2009 ]: Market Wire
BELLUS Health reports results for third quarter of fiscal 2009
[ Tue, Nov 10th 2009 ]: Market Wire
Bennett Environmental Inc. Announces Q3 Results
[ Tue, Nov 10th 2009 ]: Market Wire
HearUSA Reports Third Quarter 2009 Results
[ Tue, Nov 10th 2009 ]: Market Wire
Cytokinetics to Present Non-Clinical Data From It .. Program at the 2009 Scientific Sessions of the A
[ Tue, Nov 10th 2009 ]: Market Wire
China Aoxing Pharmaceutical Company to Present at .. Murray, Carret & Co. 2009 China Growth Conference

Protox reports 2009 third quarter results

 - Completed patient enrollment in the TRIUMPH Phase 2b study, a multi-centre, double-blinded, placebo controlled trial evaluating PRX302 in 92 males with moderate to severe benign prostatic hyperplasia (BPH). Top line results from the study are anticipated in December 2009 or early January 2010. - Announced positive 12 month data from the open-label Phase 2 study of PRX302, indicating that males with moderate to severe BPH who received an optimal dose of PRX302 continued to demonstrate significant symptomatic relief at 12 months following a single treatment. No safety issues were identified in this study and no sexual dysfunction has been reported in any of the subjects dosed to date. Detailed data from this study were presented at the 30th World Congress of the Société Internationale d'Urologie Conference on November 2nd, 2009.